Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:15:20 ON 10 NOV 2008

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 08:15:32 ON 10 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 NOV 2008 HIGHEST RN 1071762-23-6
DICTIONARY FILE UPDATES: 9 NOV 2008 HIGHEST RN 1071762-23-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading C:\Program Files\STNEXP\Queries\10572968 str 1.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l2
L2 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

```
L2              QUE  ABB=ON  PLU=ON  L1


=> s l2 sss full
FULL SEARCH INITIATED 08:16:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      232 TO ITERATE

100.0% PROCESSED      232 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L3            0 SEA SSS FUL L1

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\STNEXP\Queries\10572968 str 2.str

L4      STRUCTURE UPLOADED

=> que L4

L5   QUE L4

=> d l4
L4 HAS NO ANSWERS
L4              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l4 sss full
FULL SEARCH INITIATED 08:20:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      232 TO ITERATE

100.0% PROCESSED      232 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

L6            0 SEA SSS FUL L4

=> S "[3-[(2-Amino-benzooxazole-6-sulfonyl)-isobutyl-amino]-benzyl-2-hydr-
oxy-propyl]-carbamic acid thiazol-5-ylmethyl ester"/cn
L7            0 "[3-[(2-AMINO-BENZOOXAZOLE-6-SULFONYL)-ISOBUTYL-AMINO]-BENZYL-2-
                HYDR- OXY-PROPYL]-CARBAMIC ACID THIAZOL-5-YLMETHYL ESTER"/CN

=> S
"[3-[(2-Amino-benzooxazole-6-sulfonyl)-isobutyl-amino]-benzyl-2-hydroxy-propyl]-carb
amic acid thiazol-5-ylmethyl ester"/cn
L8            0 "[3-[(2-AMINO-BENZOOXAZOLE-6-SULFONYL)-ISOBUTYL-AMINO]-BENZYL-2-
                HYDROXY-PROPYL]-CARBAMIC ACID THIAZOL-5-YLMETHYL ESTER"/CN

=>
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
```

```
Uploading C:\Program Files\STNEXP\Queries\10572968 str 3.str

L9      STRUCTURE UPLOADED

=> que L9

L10  QUE L9

=> s l10 sss full
FULL SEARCH INITIATED 08:40:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      232 TO ITERATE

100.0% PROCESSED      232 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L11           0 SEA SSS FUL L9

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\STNEXP\Queries\10572968 str4.str

L12     STRUCTURE UPLOADED

=> que L12

L13  QUE L12

=> s l13 sss full
FULL SEARCH INITIATED 08:53:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      232 TO ITERATE

100.0% PROCESSED      232 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L14           0 SEA SSS FUL L12

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading C:\Program Files\STNEXP\Queries\10572968 str5.str

L15     STRUCTURE UPLOADED

=> que L15

L16  QUE L15

=> s l16 sss full
FULL SEARCH INITIATED 08:56:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      232 TO ITERATE

100.0% PROCESSED      232 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01
```

L17 5 SEA SSS FUL L15

=> d str

L17 ANSWER 1 OF 5 REGISTRY COPYRIGHT 2008 ACS on STN

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	933.04	933.25

FILE 'CAPLUS' ENTERED AT 08:57:38 ON 10 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Nov 2008 VOL 149 ISS 20
FILE LAST UPDATED: 9 Nov 2008 (20081109/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l17
L18 6 L17

=> d l18 1-6 ibib ab hitstr

L18 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:501142 CAPLUS
DOCUMENT NUMBER: 148:479857
TITLE: Bioavailable combinations comprising hepatitis C virus NS3/4a protease inhibitor for hepatitis C treatment
INVENTOR(S): Van't Klooster, Gerben Albert Eleutherius; De Kock, Herman Augustinus; Raboisson, Pierre Jean-Marie Bernard; Van den Eynde, Christel Florentina E.
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008046860	A2	20080424	WO 2007-EP61092	20071017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2006-122446 A 20061017
OTHER SOURCE(S): MARPAT 148:479857

AB The present invention relates to the combination comprising an hepatitis C virus (HCV) NS3/4a protease inhibitor and a compound of formula (I). The combination is useful to improve the bioavailability of the HCV NS3/4a protease inhibitor. As such, the combination is useful for treating conditions associated with the Hepatitis C virus in patients. Pharmaceutical compns. and kits comprising this combination, and processes for preparing the combination and the pharmaceutical formulations are also provided. Thus, different HCV NS3/4a protease inhibitors were tested in a metabolic blocking experiment using 3 μM test compound together with 10 μM of compound of formula I acting as a cytochrome P 450 inhibitor (or booster). Test compds. and compound of formula I were added to human liver microsomes (protein concentration 1 mg/mL) suspended in potassium phosphate buffer (pH = 7.4), to get final reaction mixture concns. of 3 μM test compound and 10 μM of compound of formula I. The experiment showed an almost complete blocking of test compound (3 μM) metabolization by addition of 10 μM of compound of formula I.

IT 1019330-02-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bioavailable combinations comprising hepatitis C virus NS3/4a protease inhibitor for hepatitis C treatment)

RN 1019330-02-9 CAPLUS
CN Carbamic acid, N-[(1R,2S)-3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1097492 CAPLUS
DOCUMENT NUMBER: 145:432164
TITLE: Use of a sulfonamide compound for improving the pharmacokinetics of a drug
INVENTOR(S): Van 't Klooster, Gerben Albert Eleutherius; Wigerinck, Piet Tom Bert Paul; De Meyer, Sandra; Baert, Lieven Elvire Colette; De Kock, Herman Augustinus
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108879	A2	20061019	WO 2006-EP61614	20060414
WO 2006108879	A3	20080110		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006234335	A1	20061019	AU 2006-234335	20060414
CA 2604799	A1	20061019	CA 2006-2604799	20060414
EP 1874307	A2	20080109	EP 2006-754743	20060414
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008535896	T	20080904	JP 2008-505907	20060414
CN 101175491	A	20080507	CN 2006-80012542	20071015
IN 2007DN07972	A	20071123	IN 2007-DN7972	20071016
PRIORITY APPLN. INFO.:			EP 2005-103035 A	20050415
			US 2005-684283P P	20050525
			WO 2006-EP61614 W	20060414

OTHER SOURCE(S): MARPAT 145:432164

AB A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P 450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease

inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention.

IT 470704-98-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of sulfonamide compound for improving pharmacokinetics of drug)

RN 470704-98-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L18 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300421 CAPLUS

DOCUMENT NUMBER: 142:373819

TITLE: Methods for the preparation of aminohydroxypropyl benzooxazolesulfonamides as intermediates in the preparation of HIV protease inhibitors

INVENTOR(S): De Kock, Herman Augustinus; Filliers, Walter Ferdinand Maria; Aelterman, Wim Albert Alex

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030739	A1	20050407	WO 2004-EP52382	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004276017	A1	20050407	AU 2004-276017	20040930
CA 2537877	A1	20050407	CA 2004-2537877	20040930
EP 1670773	A1	20060621	EP 2004-766869	20040930
EP 1670773	B1	20070207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

BR 2004014916	A	20061107	BR 2004-14916		20040930
CN 1860107	A	20061108	CN 2004-80028097		20040930
AT 353323	T	20070215	AT 2004-766869		20040930
JP 2007507468	T	20070329	JP 2006-530265		20040930
ES 2281828	T3	20071001	ES 2004-766869		20040930
IN 2006DN00930	A	20070810	IN 2006-DN930		20060222
US 20070123574	A1	20070531	US 2006-574157		20060328
MX 2006PA03575	A	20060605	MX 2006-PA3575		20060330
NO 2006001951	A	20060502	NO 2006-1951		20060502
PRIORITY APPLN. INFO.:			EP 2003-103630	A	20030930
			US 2003-507996P	P	20031002
			WO 2004-EP52382	W	20040930

OTHER SOURCE(S): CASREACT 142:373819; MARPAT 142:373819

AB Aminohydroxypropyl benzoxazolesulfonamides I [E = electrophilic moiety; PG = protecting group; R2 = H, alkyl; R3 = (un)substituted cycloalkyl, aryl, heteroaryl, alkyl; R4 = H, HO2C, (un)substituted alkyl, alkoxycarbonyl, aminocarbonyl, cycloalkyl, alkenyl, alkynyl] such as II (R5 = MeS; R6 = Me3C) are prepared as intermediates in the synthesis of HIV protease inhibitors such as II (R5 = H2N; R6 = 5-thiazolylmethyl). S-alkylation of 2-benzoxazolethione followed by regioselective sulfonylation yields an benzoxazolesulfonic acid derivative which sulfonylates an amino alc. (derived from ring opening of an epoxide with an amine) to provide I. For example, 2-mercaptobenzoxazole is methylated and the product regioselectively sulfonylated with chlorosulfonic acid and converted to the sulfonyl chloride with thionyl chloride to yield 2-(methylthio)-6-benzoxazolesulfonyl chloride. Ring opening of [1-(Boc-amino)-2-phenylethyl]oxirane (Boc = Me3COCO) with isobutylamine yields the amine PhCH2CH(NHBoc)CH(OH)CH2NHCH2CHMe2 (III). Sulfonylation of III with 2-(methylthio)-6-benzoxazolesulfonyl chloride provides II (R5 = MeS; R6 = Me3C). Heating of II (R5 = MeS; R6 = Me3C) with ammonia under pressure, cleavage of the Boc group with hydrogen chloride in isopropanol, and treatment with mono(N-hydroxysuccinimidyl) mono(5-thiazolemethyl) carbonate yields II (R5 = H2N; R6 = 5-thiazolylmethyl).

IT 848985-05-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; methods for the preparation of aminohydroxypropyl benzoxazolesulfonamides as intermediates in the preparation of HIV protease inhibitors)

RN 848985-05-7 CAPLUS

CN Carbamic acid, [3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300242 CAPLUS

DOCUMENT NUMBER: 142:349031

TITLE: Sulfonamides for inhibition of hepatitis C virus (HCV) or combined HCV and HIV infections

INVENTOR(S): Simmen, Kenneth Alan; Van Acker, Koenraad Lodewijk August; Wigerinck, Piet Tom Bert Paul; Surleraux, Dominique Louis Nestor Ghislain; Dams, Gery Karel Julia; Quirynen, Ludo Maria Marcel; Hertogs, Kurt; Pauwels, Rudi Wilfried Jan

PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.

SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030194	A1	20050407	WO 2004-EP52388	20040930
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1670448	A1	20060621	EP 2004-766871	20040930
EP 1670448	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007507469	T	20070329	JP 2006-530267	20040930
ES 2297467	T3	20080501	ES 2004-766871	20040930
US 20080234288	A1	20080925	US 2006-572968	20060321

PRIORITY APPLN. INFO.:

EP 2003-103629	A	20030930
US 2003-507535P	P	20031001
WO 2004-EP52388	W	20040930

OTHER SOURCE(S): MARPAT 142:349031

AB The invention discloses sulfonamide derivs. I (Q1 = S, O; R1 = H, C1-6 alkyl, OH, amino, halo, etc.; R2 = H, C1-6 alkyl; R3 = C1-6 alkyl, aryl, C3-7 cycloalkyl, etc.; R4 = H, C1-4 alkyloxycarbonyl, carboxyl, etc.; Q2 = substituted Ph, heterocyclyl), and N-oxides, salts, stereoisomeric forms, racemic mixts., prodrugs, and esters thereof, for the manufacture of a medicament useful for inhibiting HCV activity in a mammal infected with HCV. The invention also discloses the use of these sulfonamides in pharmaceutical compns. aimed to treat or combat combined HCV and HIV infections. In addition, the invention discloses processes for preparation of such pharmaceutical compns. The invention also discloses combinations of the sulfonamides with other anti-HCV agents and/or anti-HIV agents.

IT 848985-05-7 848985-05-7D, N-oxides, stereroisomers, or salts 848985-16-0 848985-16-0D, N-oxides, stereroisomers, or salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sulfonamides for inhibition of hepatitis C virus (HCV) or combined HCV and HIV infections)

RN 848985-05-7 CAPLUS

CN Carbamic acid, [3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)



RN 848985-05-7 CAPLUS
CN Carbamic acid, [3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)



RN 848985-16-0 CAPLUS
CN Carbamic acid, [3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (2-chloro-5-thiazolyl)methyl ester (9CI) (CA INDEX NAME)



RN 848985-16-0 CAPLUS
CN Carbamic acid, [3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (2-chloro-5-thiazolyl)methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:888736 CAPLUS
DOCUMENT NUMBER: 137:384835
TITLE: Preparation of 2-amino-benzoxazole sulfonamide as broad-spectrum HIV protease inhibitors
INVENTOR(S): Surleraux, Dominique Louis Nestor Ghislain; Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; De Bethune, Marie-Pierre T. M. M. G.; De Kock, Herman Augustinus; Tahri, Abdellah
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092595	A1	20021121	WO 2002-EP5212	20020510
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2444895	A1	20021121	CA 2002-2444895	20020510
AU 2002310818	A1	20021125	AU 2002-310818	20020510
AU 2002310818	B2	20071213		
EP 1387842	A1	20040211	EP 2002-735354	20020510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200300547	A	20040216	EE 2003-547	20020510
BR 2002009594	A	20040330	BR 2002-9594	20020510
CN 1507446	A	20040623	CN 2002-809741	20020510
HU 2004000438	A2	20040830	HU 2004-438	20020510
HU 2004000438	A3	20070828		
JP 2004534757	T	20041118	JP 2002-589479	20020510
NZ 529250	A	20050527	NZ 2002-529250	20020510
AP 1652	A	20060831	AP 2003-2904	20020510
ZA 2003007799	A	20050106	ZA 2003-7799	20031006
IN 2003DN01588	A	20070112	IN 2003-DN1588	20031006
US 20040106661	A1	20040603	US 2003-474485	20031009
BG 108309	A	20041230	BG 2003-108309	20031103
MX 2003PA10258	A	20050307	MX 2003-PA10258	20031110
PRIORITY APPLN. INFO.:			EP 2001-201732 A	20010511
			WO 2002-EP5212 W	20020510

OTHER SOURCE(S): MARPAT 137:384835

AB Title compds. I [R1, R8 = H, alkyl, alkenyl, arylalkyl, cycloalkyl, aryl, heterocyclyl, etc.; R2 = H, alkyl; L = CO, OCO, NR8CO, etc.; R3 = alkyl, cycloalkyl, aryl, etc.; R4 = H, alkoxycarbonyl, carboxy, aminocarbonyl, cycloalkyl, etc.; R5-6 = H, alkyl], N-oxides, stereoisomers, metabolites and prodrugs thereof were prepared For instance, II was prepared from the corresponding diamine (preparation described), N,N'-disuccinimidylcarbonate and 5-hydroxymethylthiazole (CH2Cl2, 6 h). Compds. of the invention are effective in inhibiting a broad range of mutant HIV strains; II had pEC50 = 8.18 against HIV-1 (Lai strain).

IT 470704-98-4P 475488-43-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-amino-benzoxazole sulfonamide as broad-spectrum HIV protease inhibitors)

RN 470704-98-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 475488-43-8 CAPLUS
CN Carbamic acid, [(1S,2R)-3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (2-chloro-5-thiazolyl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:793630 CAPLUS
DOCUMENT NUMBER: 137:310904
TITLE: Preparation of 2-(substituted-amino)benzoxazole sulfonamides as broadspectrum HIV protease inhibitors
INVENTOR(S): Surleraux, Dominique Louis Nestor Ghislain; Vendeville, Sandrine Marie Helene; Verschueren, Wim Gaston; De Bethune, Marie-Pierre T. M. M. G.; De Kock, Herman Augustinus; Tahri, Abdellah; Erra Sola, Montserrat
PATENT ASSIGNEE(S): Tibotec Pharmaceuticals Ltd., Ire.
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081478	A2	20021017	WO 2002-EP4012	20020409
WO 2002081478	A3	20030501		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,

GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2442870	A1	20021017	CA 2002-2442870		20020409
AU 2002257774	A1	20021021	AU 2002-257774		20020409
AU 2002257774	B2	20070830			
EE 200300494	A	20031215	EE 2003-494		20020409
HU 2003003744	A2	20040301	HU 2003-3744		20020409
HU 2003003744	A3	20080328			
BR 2002008796	A	20040309	BR 2002-8796		20020409
EP 1397367	A2	20040317	EP 2002-727554		20020409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004529144	T	20040924	JP 2002-579466		20020409
NZ 528954	A	20050429	NZ 2002-528954		20020409
CN 1636006	A	20050706	CN 2002-811480		20020409
AP 1544	A	20060228	AP 2003-2882		20020409
W: GM, GH, KE, LS, MW, MZ, SL, SD, SZ, TZ, UG, ZM, ZW					
BG 108218	A	20040930	BG 2003-108218		20031001
ZA 2003007683	A	20050103	ZA 2003-7683		20031001
IN 2003DN01589	A	20070223	IN 2003-DN1589		20031006
US 20040132791	A1	20040708	US 2003-474162		20031007
US 7244752	B2	20070717			
NO 2003004505	A	20031208	NO 2003-4505		20031008
MX 2003PA09179	A	20041122	MX 2003-PA9179		20031008
US 20070135447	A1	20070614	US 2007-626183		20070123
PRIORITY APPLN. INFO.:			EP 2001-201308	A	20010409
			US 2001-287704P	P	20010502
			WO 2002-EP4012	W	20020409
			US 2003-474162	A3	20031007

OTHER SOURCE(S): MARPAT 137:310904

AB Benzoxazole sulfonamides of formula I [R1 = H, alkyl, alkenyl, arylalkyl, aryl, etc.; R2 = H, alkyl; R3 = alkyl, aryl, cycloalkyl, cycloalkyl-alkyl, arylalkyl; R4 = H, alkyloxycarbonyl, carboxyl, aminocarbonyl, etc.; R5 = H, OH, alkyl, etc.; R6 = alkyloxy, aryl, aryloxy, etc.; L = CO, O-CO, NHCO, O-alkyl-CO, SO2, etc.; A = alkylene, CO, CS, SO2, etc.] are prepared as broad-spectrum HIV protease inhibitors. The compds. can also be combined with another anti-retroviral agent, and be used in assays as reference compds. or as reagents. Thus, II was prepared, and was effective in inhibiting a broad range of mutant strains in a cellular assay.

IT 470704-98-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminobenzoxazole sulfonamides as broad-spectrum HIV protease inhibitors)

RN 470704-98-4 CAPLUS

CN Carbamic acid, [(1S,2R)-3-[[(2-amino-6-benzoxazolyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, 5-thiazolylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=>
=> d his

     (FILE 'HOME' ENTERED AT 08:15:20 ON 10 NOV 2008)

     FILE 'REGISTRY' ENTERED AT 08:15:32 ON 10 NOV 2008
L1                STRUCTURE UPLOADED
L2                QUE L1
L3             0 S L2 SSS FULL
L4                STRUCTURE UPLOADED
L5                QUE L4
L6             0 S L4 SSS FULL
L7             0 S "[3-[(2-AMINO-BENZOOXAZOLE-6-SULFONYL)-ISOBUTYL-AMINO]-BENZYL
L8             0 S "[3-[(2-AMINO-BENZOOXAZOLE-6-SULFONYL)-ISOBUTYL-AMINO]-BENZYL
L9                STRUCTURE UPLOADED
L10               QUE L9
L11            0 S L10 SSS FULL
L12               STRUCTURE UPLOADED
L13               QUE L12
L14            0 S L13 SSS FULL
L15               STRUCTURE UPLOADED
L16               QUE L15
L17            5 S L16 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:57:38 ON 10 NOV 2008
L18            6 S L17
```